SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-020566
Filing Date
2024-03-07
Accepted
2024-03-06 21:49:56
Documents
16
Period of Report
2024-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0201282-8k_estrella.htm   iXBRL 8-K 42282
2 STATEMENT OF WORK NO. 001, DATED AND EFFECTIVE AS OF MARCH 4, 2024, BETWEEN ESTR ea0201282ex10-1_estrella.htm EX-10.1 52221
  Complete submission text file 0001213900-24-020566.txt   330788

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE esla-20240304.xsd EX-101.SCH 3863
4 XBRL DEFINITION FILE esla-20240304_def.xml EX-101.DEF 26753
5 XBRL LABEL FILE esla-20240304_lab.xml EX-101.LAB 36958
6 XBRL PRESENTATION FILE esla-20240304_pre.xml EX-101.PRE 25377
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0201282-8k_estrella_htm.xml XML 6000
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

IRS No.: 861314502 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 24727973
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)